A Study to Learn How Different Amounts of the Study Medicine Called PF-08103402 Are Tolerated and Act in the Body in Healthy Adults or Adults With Mild To-moderate Asthma
← catalyst calendarNCT07660731 · readout in 303 d
Sponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Randomized · Double · Basic science
Enrollment
139estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-06-17 | actual | When the study began enrolling |
| Primary completion | 2027-06-18 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-06-18 | estimated | The whole study's end, after follow-up |
| First posted | 2026-06-22 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-29 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Healthy Volunteer Study
- Healthy Adults
- Healthy Participants
- Asthma
Interventions
- Drug: PF-08103402
- Drug: Placebo
- Drug: Midazolam
Primary outcomes
what the primary-completion date above is the date OFNumber of Participants with Treatment Emergent Adverse Events (TEAEs)
measured Parts A: Up to Day 36; Part B and E: Up to Day 50
Number of Participants with Serious Adverse Events (SAEs)
measured Parts A: Up to Day 36; Part B and E: Up to Day 50
Number of Participants With Clinically Significant Change From Baseline in Laboratory Abnormalities
measured Parts A: Change From Baseline to Day 7; Part B and E: Change From Baseline to Day 17
Number of Participants With Clinically Significant Change From Baseline in Vital Signs
measured Parts A: Change From Baseline to Day 7; Part B and E: Change From Baseline to Day 17
Number of Participants With Clinically Significant Change From Baseline in Electrocardiogram (ECG) Findings
measured Parts A: Change From Baseline to Day 7; Part B and E: Change From Baseline to Day 17
Area under the curve from time zero to extrapolated infinite time (AUCinf) if data permit, otherwise (AUClast) in the fasted state
measured Pre-dose (Hour 0) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 hours post-dose on Day 1
Maximum observed plasma concentration (Cmax) in the fasted state
measured Pre-dose (Hour 0) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 hours post-dose on Day 1
Total recovery of drug-related material in urine and feces separately, and both routes combined, expressed as a percent of total dose administered
measured Pre-dose (Hour 0) and at 1.5, 2, 3, 4, 6, 8, 12 hours post-dose on Day 1 and at 24 hours post-dose (Day 2)
Maximum observed plasma concentration (Cmax)
measured Pre-dose (Hour 0) and at 0.5, 1, 2, 4, 6, 8, 12 hours post-dose on Day 1 and at 24 hours post-dose (Day 2)
Area under the curve from time zero to extrapolated infinite time (AUCinf) if data permit, otherwise AUClast
measured Pre-dose (Hour 0) and at 0.5, 1, 2, 4, 6, 8, 12 hours post-dose on Day 1 and at 24 hours post-dose (Day 2)
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed